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Abstract
To test whether: (1) psychiatrists will prescribe clozapine more often if they can delegate the monitoring tasks to an advanced 
nurse practitioner (ANP), (2) clozapine monitoring by an ANP is at least as safe as monitoring by a psychiatrist. Patients from 
23 Dutch outpatient teams were assessed for an indication for clozapine. ANPs affiliated to these teams were randomized 
to Condition A: clozapine monitoring by an ANP, or Condition B: monitoring by the psychiatrist. The safety of monitoring 
was evaluated by determining whether the weekly neutrophil measurements were performed. Staff and patients were blinded 
regarding the first hypothesis. Of the 173 patients with an indication for clozapine at baseline, only seven in Condition A 
and four in Condition B were prescribed clozapine (Odds Ratio = 2.24, 95% CI 0.61–8.21; p = 0.225). These low figures 
affected the power of this study. When we considered all patients who started with clozapine over the 15-month period 
(N = 49), the Odds Ratio was 1.90 (95% CI 0.93–3.87; p = 0.078). With regard to the safety of the monitoring of the latter 
group of patients, 71.2% of the required neutrophil measurements were performed in condition A and 67.3% in condition 
B (OR = 0.98; CI = 0.16–3.04; p = 0.98). Identifying patients with an indication for clozapine does not automatically lead 
to improved prescription rates, even when an ANP is available for the monitoring. Clozapine-monitoring performed by an 
ANP seemed as safe as that by a psychiatrist.
Keywords Clozapine · Treatment-resistant schizophrenia · Underutilization · Outpatients · Randomized trial · Nurse 
practitioner
Introduction
Despite evidence for the superiority of clozapine as therapy 
for treatment-resistant Non-Affective Psychotic Disorder 
(NAPD) (Kane et al. 1988; Siskind et al. 2016; Souza et al. 
2013), its prescription rate remains low (Bachmann et al. 
2017; Stroup et al. 2014) and clozapine initiation is often 
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delayed (Grover et al. 2015; Howes et al. 2012; Ucok et al. 
2015). This delay unnecessarily prolongs patients’ suffer-
ing and impedes their recovery. Moreover, there is some 
evidence that a delay may even diminish efficacy of clozap-
ine (Ucok et al. 2015). Important reasons for this delay and 
under-prescription may be concerns about the safety of clo-
zapine and the need for regular laboratory investigations to 
prevent potentially dangerous side-effects (Gee et al. 2014; 
Nielsen et al. 2010; Tungaraza and Farooq 2015). More 
specifically, the mandatory weekly neutrophil measure-
ments in the first months, to detect agranulocytosis, and the 
regular monitoring of other side-effects are time consuming 
and a burden to both patients and doctors. In a survey, UK 
professionals considered the deployment of dedicated staff 
to arrange and monitor this initiation phase as the factor 
most likely to increase the prescribing of clozapine (Gee 
et al. 2014). The establishment of specialised teams for the 
management of patients with treatment-resistant schizo-
phrenia including clozapine treatment in London, increased 
the number of patients who started to use this drug (Beck 
et al. 2014). However, the authors acknowledged that there 
are disadvantages to deploying additional teams: an extra 
service can cause confusion among clinicians and patients 
about the clinicians’ role and responsibilities, because 
patients have multiple appointments with different teams 
of health professionals. With a view to stimulating clozap-
ine use, the aims of this study were to test the following 
hypotheses: (1) psychiatrists prescribe clozapine more often 
if they can delegate the monitoring tasks to an advanced 
nurse practitioner (ANP); (2) monitoring by an ANP is at 
least as safe as monitoring by a psychiatrist; and (3) delega-
tion of monitoring tasks to an ANP is associated with less 




This exploratory study, set up as a cluster-randomized trial 
(study registration NTR5135), involved Dutch outpatient 
teams for patients with Non-Affective Psychotic Disorder 
(NAPD), called Flexible Assertive Community Treatment 
(FACT) teams. These teams treat patients with severe mental 
illness and are flexible in that treatment can be intensified 
in order to prevent the hospitalization of patients during a 
crisis (van Veldhuizen 2007). FACT teams are responsible 
for a specific area and their caseload consists of approxi-
mately 200–250 outpatients, most of whom have NAPD. In 
some areas, there are also Early Intervention Teams, which 
treat patients up to 5 years after the first onset of psychosis. 
These teams differ from FACT teams in that their caseloads 
are smaller and the patients younger. While teams typically 
include a psychiatrist, not all teams have an ANP. After 
at least 2 years of experience in psychiatry, Dutch nurses 
can follow a 2- or 3-year training programme to become an 
ANP in mental health care. The profession of ANP in mental 
health care in the Netherlands resembles that of a mental 
health ANP in for example the UK, France and Australia 
and that of a Psychiatric Mental Health Nurse Practitioner 
in the USA, although in some countries they are authorized 
to prescribe drugs and in other countries not. In this study, 
they did not prescribe clozapine. Given the objective of this 
study, only teams with an ANP were included.
Procedures
Before randomization, in order to prevent bias, the authors 
trained the ANPs and psychiatrists of all participating teams 
for 3 h about indications for clozapine and monitoring guide-
lines. Subsequently, the ANP and psychiatrist of each team 
assessed whether patients had an unmet indication for clo-
zapine, using a standardised procedure (van der Zalm et al. 
2018). The decision tree used during this procedure is shown 
in Online Appendix. The principle investigator (PI) was pre-
sent at this discussion and available for advice. Thereafter, 
the ANPs with their corresponding teams were randomized 
to one of two conditions: (A) intervention condition: the 
ANP performed the somatic screening of patients before 
clozapine was started, the psycho-education of the patients 
and their relatives, and the monitoring of laboratory investi-
gations and side-effects; where necessary, they asked super-
vision from the psychiatrist; or (B) treatment as usual: the 
psychiatrist performed these tasks. In both conditions, the 
psychiatrist was responsible for the decision to start clozap-
ine and for prescribing it. In order to avoid the assignment 
of an ANP to both conditions, we decided to randomize the 
ANPs instead of the teams. Psychiatrists, ANPs, and patients 
were kept blind to the first hypothesis about the number of 
patients that would start to use clozapine in each condition. 
They were only aware of the other two research questions. 
The randomization was stratified by hospital, geographical 
area, and FACT vs. Early Intervention Team.
In September 2015, the ANPs randomized to condition A 
were trained by psychiatrists of the Dutch Clozapine Expert 
Group and a mental health ANP in two sessions of 3 h each. 
The topics covered were: (1) laboratory investigations—their 
frequency, the interpretation of the results, and the necessary 
or recommended actions to be taken; (2) dangerous side-
effects of clozapine, such as agranulocytosis, myocarditis, 
and ileus, and how to prevent or detect them; (3) other side-
effects such as sedation, orthostasis, constipation, hypersali-
vation, and metabolic syndrome and how to prevent or treat 
them; (4) possible interactions between clozapine and other 
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drugs or tobacco use. The participants then had to pass a test 
of their knowledge.
All patients who started clozapine between 1 October 
2015 and 1 January 2017 were included in this trial. The 
follow-up of each patient started at the moment of clozapine 
initiation and lasted 18 weeks, a period in which weekly 
neutrophil measurements are mandatory in the Nether-
lands. Patients who started clozapine when in hospital were 
also included, provided that they were discharged within 
18 weeks. We excluded patients who started clozapine dur-
ing hospital admission and who stayed there during the first 
18 weeks. We assumed that for these patients, the decision 
to start was most often made by the responsible psychiatrist 
in the hospital. With reference to our second aim, about the 
safety of the monitoring, inpatient weeks of monitoring were 
excluded, because the focus of this study was on outpatient 
clozapine monitoring. The psychiatrist or the ANP informed 
the PI when clozapine was started. After 18 weeks, the PI 
visited the ANP or psychiatrist in his or her office. Dur-
ing this visit, the ANP or psychiatrist checked the medical 
file and provided the following information to the PI: blood 
assessments (dates and laboratory values) and duration of 
clozapine use (maximum of 18 weeks). The PI noted this 
information on structured forms. She asked explicitly for 
hazardous side-effects and, if clozapine use had been ter-
minated, she documented the reasons for discontinuation. 
Within this context, it is unlikely that the ANP or psychia-
trist invented or concealed outcomes.
Measures
In order to assess the safety of clozapine monitoring, the PI 
determined whether the mandatory weekly neutrophil meas-
urements had been performed and registered. If there was an 
interval of 9 or more days between laboratory investigations, 
she considered the measurement as missed. We reasoned 
that the number of missed measurements was an indication 
of the risk to which the patient was exposed. In addition, we 
checked the file for reports of dangerous side-effects (e.g. 
ileus, myocarditis, agranulocytosis, venous thromboembo-
lism) and investigated how soon the ANP or psychiatrist 
alerted the relevant medical specialist.
Statistical Analysis
Descriptive statistics were used to summarise demographic 
and clinical characteristics. We used multilevel logistic 
regression analysis to test for a difference in the proportion 
of patients who started to use clozapine. As a small number 
of patients without an NAPD diagnosis also started clozap-
ine, we conducted one analysis with all patients treated by 
the teams at baseline, regardless of diagnosis, and another 
analysis restricted to those with an unmet indication for this 
drug at baseline. In these analyses, patient was the first level 
and team (the psychiatrist who could prescribe the drug) the 
second level.
We used a slightly different analysis to test for differ-
ences in the number of neutrophil measurements performed. 
In this analysis, the measurements were the first level, the 
individual patient the second level, and cluster (ANP or psy-
chiatrist) the third level.
The difference in retention on clozapine was analysed 
using multilevel analysis, with patient as the first level and 
cluster (ANP or psychiatrist) as the second level. Duration 
of use was the dependent variable in this analysis. In an 
additional analysis, we compared the proportion of patients 
who stopped taking clozapine during the follow-up (χ2 test).
All multilevel analyses were random intercept models, 
adjusted for age, gender, and DSM-IV diagnosis (NAPD vs 
other diagnoses) as patient-level variables. The second anal-
ysis (of neutrophil measurements performed) was a model 
with random intercept and random slopes on patient level. 
This model was also adjusted for time (weeks) after clozap-
ine initiation, because neutrophil measurements were more 
likely to be performed in the first weeks after treatment was 
started. Descriptive statistics were performed with SPSS, 
version 22.0. The multilevel analyses were performed with 
STATA, version 13.0, using procedure GLAMM. A p-value 
of < 0.05 was considered statistically significant for all tests.
We calculated the required sample size for a cluster-
randomized trial with a power of 0.80 (one-sided test-
ing, α = 0.05). We assumed that there would be at least 15 
patients in each cluster with an unmet indication for clozap-
ine (total n = 240), of whom on average 50% would actually 
start with this drug (N = 120). We also assumed that in our 
intervention condition twice as many patients would start 
with clozapine (OR = 2) and that the coefficient of intraclus-
ter correlation was 0.6. The results showed that we needed 
eight clusters in each condition (Hayes and Bennet 1999).
Results
Teams and Patients
Four psychiatric institutes in different Dutch regions agreed 
to participate in this trial. Of the five Early Intervention 
Teams and 29 FACT teams of these institutes, three Early 
Intervention Teams and 20 FACT teams were eligible, see 
Fig. 1. Seventeen ANPs worked for these 23 teams. Some 
ANPs worked for two teams, but there were no teams with 
more than one ANP. The ANPs were randomized into one 
of the two conditions: 9 ANPs, working for 13 teams, were 
assigned to condition A and 8 ANPs, working for ten teams, 
to condition B. At the start of the 15-month inclusion period, 
3839 patients were being treated by these teams. There were 
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34 teams assessed for eligibility 
11 teams excluded
- no advanced nurse 
practitioner (ANP) in team
28 patients started 
on clozapine 
- 5 re-started 
- 16 developed an 
indication during the 
trial 
- 7 had no diagnosis 
of non-affective 
psychotic disorder at 
the moment of the 
screening yet
82 patients with an 
unmet indication for
clozapine 
Allocated to condition A, intervention 
- 13 teams 
- 9 ANPs 
- 2216 patients
91 patients with an 
unmet indication for
clozapine 




4 patients started on 
clozapine
23 participating teams 
17 participating ANPs 
7 patients started on 
clozapine 
10 patients started 
on clozapine 
- 2 re-started
- 8 developed an 
indication during the 
trial 
2134 patients 




without an unmet 
indication for 
clozapine 
Fig. 1  Flow diagram of teams and participants
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no significant differences in mean age or gender between the 
patients of the two conditions, but there were minor differ-
ences in proportions of diagnoses. The baseline character-
istics are shown in Table 1. Screening patients for an unmet 
indication for clozapine at baseline identified 82 patients in 
condition A (3.7% of all patients) and 91 patients in condi-
tion B (5.6% of all patients), see Fig. 1.
Prescription of Clozapine
Of the 173 patients with an unmet indication for clozapine, 
only 7 patients in condition A and 4 in condition B were 
started on clozapine (i.e. 6.4% of all patients with an unmet 
indication). The baseline characteristics of these patients are 
presented in Table 2. The odds ratio for starting clozapine in 
condition A compared to condition B, adjusted for age and 
gender was 2.24, CI 0.61–8.21; p = 0.225.
The reasons for not prescribing clozapine to patients were 
not systematically studied and this data was not recorded 
in the files. However, at baseline, psychiatrists and ANPs 
mentioned reasons for not prescribing clozapine to patients 
with an indication. A frequently mentioned reason was that 
they expected the patient not to collaborate with lab exams. 
Another frequently mentioned reason was non-compliance 
with oral medication in the past and therefore the need to 
stay on long-acting injectables. That the patient was doing 
much better than several years before and starting clozapine 
was not worth the risk, was also mentioned several times. 
Additional analysis on prescription of clozapine.
Apart from the patients with an unmet indication for clo-
zapine at baseline, there were other patients in the teams 
who started with clozapine. Those patients either re-started 
the drug, developed an indication during the trial (due to 
an increase of positive symptoms or to a lack of effect of 
other antipsychotics), or did not have an NAPD diagnosis at 
baseline (see Fig. 1). In total, 49 started on clozapine during 
Table 1  Baseline characteristics of 3839 patients from 23 teams who 
participated in a cluster-randomized trial to compare clozapine moni-
toring by advanced nurse practitioners and psychiatrists
* Condition A: delegation of clozapine-monitoring tasks to a trained 
advanced nurse practitioner
** Condition B: treatment as usual, clozapine monitoring by a psychia-
trist
*** χ2-test: age, gender, diagnosis (schizophrenia, schizoaffective dis-
order, schizophreniform disorder, psychotic disorder not otherwise 









Age, years: mean (S.D) 46.6 (12.4) 45.9 (12.6) 0.095
Male, n (%) 1353 (61.2) 1033 (63.7) 0.116
DSM-IV diagnosis, n (%) .003
 Schizophrenia 885 (39.9) 734 (45.3)
 Schizoaffective disorder 215 (9.7) 154 (9.5)
 Schizophreniform 
disorder
13 (0.6) 17 (1.0)
 Psychotic disorder not 
otherwise specified
367 (16.6) 258 (15.9)
 Other diagnosis/
unknown
737 (33.2) 460 (28.3)
Table 2  Sociodemographic and clinical characteristics of patients who started clozapine in a cluster-randomized trial comparing clozapine mon-
itoring by advanced nurse practitioners and psychiatrists
* Condition A: delegation of clozapine-monitoring tasks to a trained advanced nurse practitioner
** Condition B: treatment as usual, clozapine monitoring by a psychiatrist
*** χ2-test: age, gender, diagnosis (schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, 
or other diagnosis)
Characteristic Starters with indication at baseline
N = 11
Starters with indication at baseline or thereafter
N = 49
Condition A*, interven-
tion (n = 7)
Condition B**, treatment as 
usual (n = 4)
Condition A*, interven-
tion (n = 35)
Condition B**, 
treatment as usual 
(n = 14)
Age, years: mean (S.D) 48.1 (3.1) 55.5 (6.4) 45.7 (12.3) 45.6 (14.0)
Male, n (%) 4 (57.1) 2 (50.0) 22 (62.9) 11 (78.6)
DSM-IV diagnosis, n (%)
 Schizophrenia 4 (57.1) 1 (25.0) 20 (57.1) 9 (64.3)
 Schizoaffective disorder 2 (28.6) 2 (50) 3 (8.6) 2 (14.3)
 Schizophreniform disorder -
 Psychotic disorder not otherwise 
specified
1 (14.3) 1 (25.0) 7 (20.0) 3 (21.4)
 Other diagnosis 5 (14.3)
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the study period: 35 in condition A and 14 in condition B. 
Table 2 shows the characteristics of these patients. Taking 
all 3839 patients into account, the odds ratio for starting 
clozapine in condition A compared to condition B, adjusted 
for age, gender and NAPD-diagnosis (yes/no) was 1.90 (95% 
CI 0.93–3.87; p = 0.078).
There were large differences between the teams in pre-
scribing clozapine, see Supplementary Table S1. Psychia-
trists who had spoken negatively about clozapine hardly 
prescribed it, regardless of the condition they were in. Con-
versely, psychiatrists with a strong positive attitude toward 
clozapine regularly prescribed it, also regardless of the con-
dition they were in. On the other hand, some psychiatrists in 
condition A collaborating with three ANPs informed us that 
they were very glad that they were allocated to the interven-
tion condition, because now they could start with ambula-
tory clozapine initiation. They stated that they had not pre-
scribed clozapine if they had been allocated to condition 
B. Supplementary Table S1 shows the differences per team 
in patients on clozapine, with an indication for clozapine 
and who started with this drug. This table also shows that 
there were more patients newly admitted to the ambulatory 
team during the study period who started to use clozapine 
in condition A (N = 13) compared to condition B (N = 4). 
There was an in- and out-flow of patients during the inclu-
sion period and it was not possible to keep track of all these 
changes. Nonetheless, differences between the conditions 
were in line with the first hypothesis.
Safety of Clozapine Monitoring
For our second question on safety of clozapine monitoring, 
we included all patients who started clozapine in the par-
ticipating teams (n = 49). In condition A, 8 patients started 
clozapine as an inpatient and another patient was admit-
ted twice during the first 18 weeks. The mean duration of 
admission, for these 9 patients, was 6.9 weeks (SD 3.8). In 
condition B, 7 patients started clozapine as inpatients. Their 
mean duration of admission was 8.7 weeks (SD 4.9). After 
the exclusion of the weeks of inpatient treatment (mean 
1.8 weeks in condition A and 4.4 weeks in condition B) 
and the time between premature stopping of clozapine and 
the end of follow-up, neutrophil measurement for the 49 
included patients was mandatory for 682 weeks (517 in Con-
dition A and 165 in condition B). Overall, 368 neutrophil 
measurements in condition A were performed as required 
(71.2%) and 111 in condition B (67.3%) (OR, adjusted for 
age, gender, and weeks after start 0.98; 95% CI, 0.16–6.04; 
p = 0.982). The proportion of neutrophil measurements 
carried out by one ANP or psychiatrist varied consider-
ably. In condition A, this proportion ranged from 30.6 to 
87.2% and in condition B from 0 to 97%. Supplementary 
Table 2 shows these proportions per cluster. No dangerous 
side-effects occurred in either condition. The reasons for 
missed neutrophil counts varied. In most cases the patients 
received a laboratory form, but did not go to the laboratory. 
In one particular area neutrophil measurements were missed 
because of a failing laboratory. For example, the wrong tests 
were performed or the laboratory assistant went to the wrong 
address. Holidays of patients were another reason for missed 
lab exams. A psychiatrist failed to notice that one patient 
missed all laboratory tests. Missing laboratory exams was 
only in one patient the reason to stop clozapine. This psy-
chiatrist made the decision when the patient had a fever and 
persisted in refusing neutrophil measurements.
Duration of Clozapine Use
For the analysis on duration of use, we also included all 
patients who started clozapine in the participating teams 
(n = 49). There were no significant differences in the reten-
tion on clozapine—the mean duration of use (including 
inpatient weeks of use)was 16.53 (SD 4.5) weeks in condi-
tion A and 15.96 (SD 3.4) weeks in condition B (b = 0.31; 
95% CI −2.26–2.88; p = 0.815). In condition A, 11.4% of 
the clozapine starters stopped taking the drug prematurely 
(< 18 weeks) compared to 28.6% in condition B (χ2 = 2.15; 
df = 1; p = 0.142). One patient in condition B stopped to use 
clozapine after 7 weeks because it was not effective and one 
patient in condition A had to stop clozapine because of a 
fever in combination with the refusal to go to the laboratory. 
In all other patients (n = 6), the reason for discontinuation 
were the side-effects of clozapine. This was a shared deci-
sion for all patients except one.
Discussion
Main Findings
We tested the hypotheses that psychiatrists would prescribe 
clozapine more often if they could delegate the monitor-
ing tasks to an ANP, that monitoring by an ANP is at least 
as safe as monitoring by a psychiatrist, and that delegation 
of monitoring tasks to an ANP is associated with a longer 
retention on clozapine. Our findings were consistent with the 
first hypothesis, but failed to reach the conventional level of 
statistical significance, most likely due to a lack of statistical 
power. The OR was close to the OR assumed in our power 
calculation, but the number of patients with an unfulfilled 
indication for clozapine was smaller than we expected. In 
addition, the number of patients who started with this drug 
in either condition were much smaller than expected. We 
conclude that even when an ANP is present for support, 
Dutch psychiatrists still fail to start clozapine for the vast 
majority of patients identified as having potential benefit 
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from clozapine. We can only speculate about the causes of 
this hesitation. Possible reasons are the side-effects of clo-
zapine, some of which are dangerous and require a prompt 
and adequate reaction, or an absence of trust in the potential 
benefits from this drug.
Clozapine monitoring by an ANP seems as safe, in terms 
of performed and recorded neutrophil measurements, as that 
done by a psychiatrist. Patients monitored by an ANP tended 
to stay on treatment for longer than patients monitored by 
a psychiatrist, but the difference was small and statistically 
not significant.
Comparison with Other Studies
This study was the first randomized controlled trial to exam-
ine the effect of an intervention to stimulate the use of clo-
zapine. The findings of our study are in line with those of 
the study of Goren et al. (2016). In their study, Goren et al. 
interviewed psychiatrists over the phone to identify facilita-
tors of and barriers to clozapine use. They concluded that 
the involvement of ANPs and clinical pharmacists in clozap-
ine teams was associated with high clozapine prescription 
rates. This multidisciplinary approach is comparable to the 
ANP condition in our study, where all ANPs collaborated 
with a psychiatrist. As for the mandatory weekly neutrophil 
measurements, it is difficult to compare the results between 
different settings. Of note, in the Netherlands, there is no 
manufacturer-organised mandatory service or database for 
haematological monitoring. It is the responsibility of the 
physician to organise these weekly laboratory investigations. 
To our knowledge, only one other study reported the fre-
quency of neutrophil measurements after the initiation of 
clozapine, with measurements being performed during the 
first 18 weeks at a mean interval of 25 days (Ingimarsson 
et al. 2016). This is less often than in our study.
In order to compare sole nurse-led clozapine services to 
physician-led teams, Gage et al. (2015) interviewed patients 
and concluded that clinics run by a nurse could effectively 
provide clozapine-monitoring services. However, the lack of 
direct access to a physician led to an increased use of com-
munity psychiatric services and to more hospital psychiatrist 
appointments. This argues for a multidisciplinary approach 
within one team, as occurred in the ANP condition in our 
study.
Strengths and Limitations
A strength of this study is that all patients, psychiatrists, 
and ANPs were (and remained) blind to the first hypoth-
esis. Another strength is that this real-world study involved 
patients and healthcare professionals from a non-academic 
setting, which is representative for many European ser-
vices. Additionally, multidisciplinary outpatient teams like 
the FACT-teams in the Netherlands are comparable to ser-
vices in other European countries (Rosenheck et al. 2016; 
Valdes-Stauber et al. 2014). However, some limitations 
need to be addressed. First, since the proportion of patients 
starting clozapine was smaller than expected, especially 
among those with an indication at baseline, the power of 
the trial to address the research questions was insufficient. 
Although we did not approach our second question as a 
non-inferiority analysis, the results do not indicate that 
the monitoring in our intervention condition was less safe. 
Second, the appraisal of the safety of the monitoring was 
limited to the number of neutrophil measurements per-
formed and to the reporting of dangerous side-effects in 
the patient files. Information on whether the results of the 
laboratory investigations were checked in time is usually 
not recorded. It was not possible to investigate whether 
other aspects, such as constipation and blood pressure, 
were monitored as required by guidelines. Third, the data-
collection was not performed by blinded research assis-
tants. We believe that asking permission for an independ-
ent researcher to check the file, would have lowered the 
number of participants, because many patients are hesitant 
to start on clozapine and some of them are paranoid. In 
order to prevent bias, the PI was present at the moment 
the ANP or the psychiatrist checked the files for the data-
collection. Fourth, in condition A, there was a collabora-
tion between ANP and psychiatrists, which may have been 
an advantage. However, since ANPs cannot be responsible 
for the total of clozapine care, a small involvement of a 
psychiatrist, as in our condition A, corresponds to reality. 
Fifth, the training of psychiatrists and ANPs preceding the 
trial and the assessment of patients for an unmet indica-
tion for clozapine, could have increased the number of 
patients to start with clozapine. However, the number of 
patients that started was much lower than expected and 
this effect should be the same for both conditions. In addi-
tion, the knowledge of being in a study on safety of clo-
zapine monitoring may have increased the number of lab 
exams. Since both psychiatrists and ANPs indicated that 
they did not want to be inferior to those in the other condi-
tion, we expected this effect to be similar in the conditions. 
Sixth, we were unable to adjust for the availability of a 
point-of-care (POC) device to test neutrophils, because 
only one team was in possession of such a device at the 
start of the follow-up (a team in condition B). Bogers et al. 
(2015) found that patients preferred POC testing and that 
this method moderately influenced their motivation for 
clozapine therapy. The availability of POC testing could, 
therefore, have led to more patients starting with clozapine 
and to a longer retention. Finally, the results of this study 
are only generalizable to countries where prescribers are 
responsible for clozapine monitoring, so without an inde-
pendent clozapine monitoring agency.
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Implications
The results of this trial show that identifying patients with 
an indication for clozapine does not automatically lead 
to improved prescription rates. The results also suggest 
that some prescribers do not prescribe clozapine, irrespec-
tive of the condition they were in. In future research on 
interventions to stimulate use of clozapine, the attitude 
of the prescriber may be a better target for interventions. 
However, given the odds ratio and the p-value found in 
this small sample, we are confident that the use of clozap-
ine can be stimulated by delegating the labour-intensive 
monitoring tasks to an ANP without compromising safety. 
This strategy can lead to earlier recovery from chronic 
psychosis and better patient outcome.
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